Literature DB >> 19756998

Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis.

Boris K Pliyev1, Mikhail Yu Menshikov.   

Abstract

Soluble form of the urokinase-type plasminogen activator receptor (suPAR) is markedly increased in biological fluids during different inflammatory conditions. It has previously been observed that the highest suPAR concentrations in inflammatory exudates tend to be associated with the presence of high number of neutrophils. Guided by this observation and our recent finding that activated neutrophils release suPAR we investigated whether neutrophils can be a source of suPAR during the inflammatory response in vivo. To address this question we conducted the comparative analysis of neutrophils isolated from the paired samples of synovial fluid (SF) and peripheral blood (PB) of rheumatoid arthritis patients. Freshly isolated SF neutrophils released significantly (p < 0.01) higher amounts of suPAR compared with PB neutrophils. We demonstrated that neutrophils from both sources release predominantly the truncated D2D3 form of suPAR. Migration of formyl peptide receptor-like 1 (FPRL1)-transfected human embryonic kidney (HEK) 293 cells toward the supernatants harvested from in vitro cultured SF neutrophils was significantly diminished when D2D3 form of suPAR was immunodepleted from the supernatants. Taken together, these data demonstrate that neutrophils, first, contribute to or are responsible for the generation of the increased suPAR levels during the inflammatory response and, second, release the chemotactically active form of suPAR that might be involved in the recruitment of formyl peptide receptors-expressing leukocytes into the inflamed tissues.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19756998     DOI: 10.1007/s10753-009-9152-0

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  43 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  Circulating levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR) in patients with atopic eczema/dermatitis syndrome.

Authors:  Alicja Kasperska-Zajac; Barbara Rogala
Journal:  Inflammation       Date:  2005-04       Impact factor: 4.092

3.  Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR).

Authors:  Massimo Resnati; Isabella Pallavicini; Rita Daverio; Nicolai Sidenius; Pierangelo Bonini; Francesco Blasi
Journal:  J Immunol Methods       Date:  2005-12-19       Impact factor: 2.303

4.  Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization.

Authors:  Carmine Selleri; Nunzia Montuori; Patrizia Ricci; Valeria Visconte; Maria Vincenza Carriero; Nicolai Sidenius; Bianca Serio; Francesco Blasi; Bruno Rotoli; Guido Rossi; Pia Ragno
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

5.  Functional and genomic changes induced by alveolar transmigration in human neutrophils.

Authors:  Christopher D Coldren; Jerry A Nick; Katie R Poch; Malcolm D Woolum; Brian W Fouty; James M O'Brien; Michael P Gruber; Martin R Zamora; Daiva Svetkauskaite; Don A Richter; Qianbin He; Jong Sung Park; Katherine H Overdier; Edward Abraham; Mark W Geraci
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-07-21       Impact factor: 5.464

6.  Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo.

Authors:  I F Mizukami; N E Faulkner; M R Gyetko; R G Sitrin; R F Todd
Journal:  Blood       Date:  1995-07-01       Impact factor: 22.113

7.  Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling.

Authors:  Yoe-Sik Bae; Ha Young Lee; Eun Jin Jo; Jung Im Kim; Hyun-Kyu Kang; Richard D Ye; Jong-Young Kwak; Sung Ho Ryu
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

8.  Neutrophil expression of tumour necrosis factor receptors (TNF-R) and of activation markers (CD11b, CD43, CD63) in rheumatoid arthritis.

Authors:  S Lopez; L Halbwachs-Mecarelli; P Ravaud; G Bessou; M Dougados; F Porteu
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

9.  Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor.

Authors:  Annapaola Andolfo; William R English; Massimo Resnati; Gillian Murphy; Francesco Blasi; Nicolai Sidenius
Journal:  Thromb Haemost       Date:  2002-08       Impact factor: 5.249

10.  Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis.

Authors:  Judith Auer; Markus Bläss; Hendrik Schulze-Koops; Stefan Russwurm; Thomas Nagel; Joachim R Kalden; Martin Röllinghoff; Horst Ulrich Beuscher
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  15 in total

1.  Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.

Authors:  Jutta Gellermann; Franz Schaefer; Uwe Querfeld
Journal:  Pediatr Nephrol       Date:  2014-08-17       Impact factor: 3.714

2.  Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.

Authors:  Yizhi Xiao; Hui Luo; Bin Zhou; Xiaodan Dai; Jing Huang; Liping Duan; Yunhui You; Weiru Zhang; Hongjun Zhao; Yanli Xie; Yaou Zhou; Wangbin Ning; Tong Li; Sijia Liu; Honglin Zhu; Xiaoyun Xie; Ying Jiang; Shiyao Wu; Weijia He; Yisha Li
Journal:  Rheumatol Int       Date:  2016-11-22       Impact factor: 2.631

3.  Receptor cleavage reduces the fluid shear response in neutrophils of the spontaneously hypertensive rat.

Authors:  Angela Y Chen; Frank A DeLano; Shakti R Valdez; Jessica N Ha; Hainsworth Y Shin; Geert W Schmid-Schönbein
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-22       Impact factor: 4.249

4.  Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study.

Authors:  A Uzawa; Y Kojima; Y Ozawa; M Yasuda; Y Onishi; H Akamine; N Kawaguchi; K Himuro; S Kuwabara
Journal:  Clin Exp Immunol       Date:  2020-08-10       Impact factor: 4.330

5.  Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.

Authors:  Muhammad S El-Mekkawy; Nagwan Y Saleh; Ahmed A Sonbol
Journal:  Indian J Pediatr       Date:  2016-03-10       Impact factor: 1.967

6.  Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA.

Authors:  Juha Onatsu; Mikko Taina; Pirjo Mustonen; Marja Hedman; Antti Muuronen; Otso Arponen; Miika Korhonen; Pekka Jäkälä; Ritva Vanninen; Kari Pulkki
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

7.  Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.

Authors:  Özlem Akdoğan; Ayşegül Atak Yücel; Zeynep Gök Sargin; Cemile Sönmez; Güldal Esendağli Yilmaz; Seren Özenirler
Journal:  J Clin Exp Hepatol       Date:  2018-02-16

Review 8.  Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.

Authors:  Yara Backes; Koenraad F van der Sluijs; David P Mackie; Frank Tacke; Alexander Koch; Jyrki J Tenhunen; Marcus J Schultz
Journal:  Intensive Care Med       Date:  2012-06-16       Impact factor: 17.440

9.  Serum Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated with Low Left Ventricular Ejection Fraction and Elevated Plasma Brain-Type Natriuretic Peptide Level.

Authors:  Shu-Ichi Fujita; Suguru Tanaka; Daichi Maeda; Hideaki Morita; Tomohiro Fujisaka; Yoshihiro Takeda; Takahide Ito; Nobukazu Ishizaka
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

10.  Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure.

Authors:  Zuxiong Huang; Ning Wang; Shuiwen Huang; Yi Chen; Shida Yang; Qiaorong Gan; Hanhui Ye; Baorong Liu; Chen Pan
Journal:  Gastroenterol Res Pract       Date:  2019-05-02       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.